Antibody discovery remains one of the most challenging aspects in antibody therapeutic development. Novel proteomics-based approaches to antibody discovery offer a promising strategy to overcome roadblocks often associated with other discovery technologies. With REpAb technology, antibody discovery with mass spectrometry enables the exploration of the natural immune repertoire with unparalleled antibody diversity and creates a pathway for the discovery of novel antibodies from human serum.
